H.C. Wainwright raised the firm’s price target on Neurocrine (NBIX) to $215 from $192 and keeps a Buy rating on the shares. The firm updated the company’s model to reflect the Soleno Therapeutics (SLNO) acquisition.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $166 from $151 at Baird
- Neurocrine price target raised to $242 from $204 at Citi
- Neurocrine price target raised to $200 from $164 at Canaccord
- Neurocrine Biosciences: Vykat XR Acquisition Unlocks Diversified Growth and Upside Potential Despite Near-Term Pipeline Lull
- Neurocrine price target raised to $220 from $192 at Oppenheimer